ArticleJournal of health economics and outcomes research2019
No Apparent Workup for most new Indeterminate Pulmonary Nodules in US Commercially-Insured Patients.
Article in Journal of health economics and outcomes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 28 citations in OpenAlex.
- Two-Year Lung Cancer Incidence Among Patients Who Receive a Radiologist Recommendation for Chest CT in Neck CT and MRI Reports.Journal of the American College of Radiology : JACR · 2026Observational
- Real-world before-and-after evaluation of AI support for lung cancer diagnosis at three US lung nodule clinics.PloS one · 2026Article
- Incidental Pulmonary Nodules: What Should We Do in 2026?Respiration; international review of thoracic diseases · 2026Review
- Employment of artificial intelligence for early lung cancer diagnosis: a retrospective cohort study.BMJ open respiratory research · 2025Article
- Pulmonary nodules in Denmark: occurrence, resource use, and risk of lung cancer and death.Acta oncologica (Stockholm, Sweden) · 2025Article
- Incidental pulmonary nodule management in Canada: exploring current state through a narrative literature review and expert interviews.Journal of thoracic disease · 2024Review
- Article
- Evaluation of Lung Cancer Risk Among Persons Undergoing Screening or Guideline-Concordant Monitoring of Lung Nodules in the Mississippi Delta.JAMA network open · 2023Article
- Prevalence and consequences of non-adherence to an evidence-based approach for incidental pulmonary nodules.PloS one · 2022Article
- Incidental Pulmonary Nodules - What Do We Know in 2022.Respiration; international review of thoracic diseases · 2022Review
- Understanding the patient journey to diagnosis of lung cancer.BMC cancer · 2021Article
- Development and outcomes of a comprehensive multidisciplinary incidental lung nodule and lung cancer screening program.BMC pulmonary medicine · 2020Article
- Cost-effectiveness analysis of LungLB for the clinical management of patients with indeterminate pulmonary nodules.Journal of medical economicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA recent study estimated that more than 1.5 million Americans have an indeterminate pulmonary nodule (IPN) identified on a chest computed tomography (CT) scan each year outside of lung cancer screening programs. However, the cost and pattern of subsequent IPN workup have not been described for real-world settings.
objectivesTo examine the pattern and cost of IPN workup in real-world practice using insurer administrative claims data for commercially-insured individuals.
methodsThe primary source for this retrospective observational study was the MarketScan
resultsOf the 15 064 patients in the study population, only 5471 (36%) received any subsequent workup. The average and median costs of workup for these patients were $3270 and $2068, respectively. Spread across the commercially-insured population, the workup is estimated to cost between $1 and $2 per member per year.
conclusionsThe majority of commercially-insured members with newly identified IPNs do not appear to have any guideline-recommended workup, despite a low incremental cost of such workup services on a population basis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.